share_log

康方生物：內幕消息公告 正面盈利預告

AKESO: INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT

香港交易所 ·  Mar 4 18:32
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」）於2024年3月4日發布正面盈利預告，預期截至2023年12月31日止年度將錄得不低於人民幣18.5億元的利潤，相較於2022年同期的虧損約人民幣14.2億元，標誌著公司首次實現年度盈利。此轉虧為盈主要得益於與Summit Therapeutics Inc簽訂的合作許可協議，從中獲得的首付款大部分已確認為許可費收入，約人民幣29億元。此外，公司創新產品開坦尼®的銷售收入穩步提升，以及有效的成本控制亦為盈利貢獻。董事會強調，此盈利預告基於未經審核的初步評估，最終數字將於2024年3月公布的年度業績公告中確認。股東及潛在投資者應謹慎行事。
康方生物科技（開曼）有限公司（「康方生物」）於2024年3月4日發布正面盈利預告，預期截至2023年12月31日止年度將錄得不低於人民幣18.5億元的利潤，相較於2022年同期的虧損約人民幣14.2億元，標誌著公司首次實現年度盈利。此轉虧為盈主要得益於與Summit Therapeutics Inc簽訂的合作許可協議，從中獲得的首付款大部分已確認為許可費收入，約人民幣29億元。此外，公司創新產品開坦尼®的銷售收入穩步提升，以及有效的成本控制亦為盈利貢獻。董事會強調，此盈利預告基於未經審核的初步評估，最終數字將於2024年3月公布的年度業績公告中確認。股東及潛在投資者應謹慎行事。
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) issued a positive profit forecast on March 4, 2024, expecting to record a profit of no less than RMB18.5 billion for the year ended December 31, 2023, compared to a loss of about RMB14.2 billion for the same period in 2022, marking the first time for the company. Profit for the current year. The loss to earnings is mainly due to a cooperative licensing agreement with Summit Therapeutics Inc. The majority of the initial payments received have been confirmed as license fee revenue of approximately RMB29 billion. In addition, the company's innovative product, Kaitani®, increased sales revenue and effective cost control contributed to profitability. The Board underlines that this profit forecast is based on an unaudited preliminary assessment, the final figures will be confirmed in the Annual Results Announcement published in March 2024. Shareholders and potential investors should exercise caution.
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) issued a positive profit forecast on March 4, 2024, expecting to record a profit of no less than RMB18.5 billion for the year ended December 31, 2023, compared to a loss of about RMB14.2 billion for the same period in 2022, marking the first time for the company. Profit for the current year. The loss to earnings is mainly due to a cooperative licensing agreement with Summit Therapeutics Inc. The majority of the initial payments received have been confirmed as license fee revenue of approximately RMB29 billion. In addition, the company's innovative product, Kaitani®, increased sales revenue and effective cost control contributed to profitability. The Board underlines that this profit forecast is based on an unaudited preliminary assessment, the final figures will be confirmed in the Annual Results Announcement published in March 2024. Shareholders and potential investors should exercise caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more